Neues zur symptomatischen MS-Therapie: Teil 5 – Fatigue
- 384 Downloads
Zusammenfassung
Die symptomatische Behandlung der multiplen Sklerose (MS) hat heutzutage neben der Immuntherapie einen hohen Stellenwert im umfassenden Therapiekonzept dieser chronischen Erkrankung, trägt sie doch erheblich zu einer Verringerung von Beeinträchtigungen im Alltag, sozialen und beruflichen Leben sowie zur Verbesserung der Lebensqualität bei. Seit der letzten umfassenden Bestandsaufnahme 2004 in dieser Zeitschrift sowie den Leitlinien der DGN(Deutschen Gesellschaft für Neurologie)/KKN-MS(Klinisches Kompetenznetz Multiple Sklerose) zu Diagnose und Therapie der MS 2014 haben sich Neuerungen und Ergänzungen in den Bereichen Mobilität, Blasenfunktion, Sexualfunktionen, Augen, Fatigue, Kognition und Rehabilitation ergeben. Diese sowie weitere Aspekte (Messmethoden des jeweiligen Symptoms, Therapieziele, Gesamtbehandlungsplan) werden in einer Reihe aus 6 Einzelbeiträgen vorgestellt. Hier soll auf die Fatigue eingegangen werden.
Schlüsselwörter
Multiple Sklerose Symptomatische Therapie Lebensqualität FatigueNew aspects of symptomatic MS treatment: Part 5 – fatigue
Abstract
The symptomatic treatment of multiple sclerosis (MS) is nowadays of similar importance as immunotherapy within a comprehensive treatment concept of this chronic disease. It makes a considerable contribution to the reduction of disabilities in activities of daily living as well as social and occupational life. Moreover, symptomatic treatment is of great importance for amelioration of the quality of life. Since our last survey of symptomatic MS treatment in 2004 and publication of the guidelines of the German Neurological Society and the Clinical Competence Network Multiple Sclerosis (Klinisches Kompetenznetz Multiple Sklerose, KKN-MS) in 2014 several developments within the topics of mobility, bladder and sexual function, vision, fatigue, cognition and rehabilitation have taken place. These new findings together with further aspects of disease measurement methods and overall treatment strategies of the respective symptoms as well as treatment goals are introduced in a series of 6 individual contributions. In this article the symptom of fatigue is discussed.
Keywords
Multiple sclerosis Symptomatic treatment Quality of life FatigueNotes
Danksagung
Wir bedanken uns bei der Firma Almirall Hermal für finanzielle Hilfe bei der technischen Erstellung des Manuskripts, ebenso bei Frau Dr. U. Essner sowie Frau Dr. P. Hundehege und Frau L. Forster (Neurologische Universitätsklinik Münster) für ihre Hilfe bei der Erstellung des Manuskripts.
Einhaltung ethischer Richtlinien
Interessenkonflikt
T. Henze erhielt Vortragshonorare und Aufwandsentschädigungen für Advisory Boards von Almirall, Coloplast, Genzyme, Novartis, Sanofi. Interessenkonflikte bestehen nicht. W. Feneberg erhielt Vortragshonorare, Aufwandsentschädigungen für Advisory Boards bzw. Unterstützung bei Fortbildungen von Almirall, Bayer, Biogen Idec, Coloplast, Genzyme, Ipsen, Merz, Novartis, Sanofi-Aventis. Interessenkonflikte bestehen nicht. P. Flachenecker hat Honorare für Vorträge und Beratungstätigkeiten von den Firmen Almirall, Bayer, Biogen Idec, Genzyme, Novartis, Merck Serono, Roche und Teva erhalten und an industriegesponsorten Studien von Biogen Idec und Novartis teilgenommen. Interessenkonflikte bestehen nicht. H. Albrecht hat Zahlungen für Reisekosten und/oder Fortbildungsveranstaltungen und/oder Studien erhalten von Almirall, Bayer Healthcare, Biogen Idec, Genzyme-Sanofi, Merck Serono, Teva. S.G. Meuth erhielt Vortragshonorare, Aufwandsentschädigungen für Advisory Boards bzw. Unterstützung bei Fortbildungen und/oder Projektförderung von Bayer, Bayer Schering, Biogen Idec, Genzyme, Merck Serono, Merck Sharp & Dohme, Novartis, Novo Nordisk, Sanofi-Aventis und Teva. D. Seidel und M. Starck geben an, dass kein Interessenkonflikt besteht.
Dieser Beitrag beinhaltet keine von den Autoren durchgeführten Studien an Menschen oder Tieren.
Literatur
- 1.Henze T, Rieckmann P, Toyka KV (2004) Symptomatische Therapie der Multiplen Sklerose. Nervenarzt 75((Supp.1):2–39PubMedGoogle Scholar
- 2.Mathiowetz V (2003) Test-retest reliability and convergent validity of the Fatigue Impact Scale for persons with multiple sclerosis. Am J Occup Ther 57:389–395CrossRefPubMedGoogle Scholar
- 3.Penner IK, Raselli C, Stocklin M et al (2009) The Fatigue Scale for Motor and Cognitive Functions (FSMC): validation of a new instrument to assess multiple sclerosis-related fatigue. Mult Scler 15:1509–1517CrossRefPubMedGoogle Scholar
- 4.Flachenecker P (2015) Fatigue bei Multipler Sklerose. Diagnostische und therapeutische Aspekte. Nervenheilkunde 34:685–689CrossRefGoogle Scholar
- 5.Flachenecker P, Kümpfel T, Kallmann B et al (2002) Fatigue in multiple sclerosis: a comparison of different rating scales and correlation to clinical parameters. Mult Scler 8:523–526CrossRefPubMedGoogle Scholar
- 6.Khan F, Amatya B, Galea M (2014) Management of fatigue in persons with multiple sclerosis. Front Neurol 5:177CrossRefPubMedPubMedCentralGoogle Scholar
- 7.Flachenecker P (2012) Autoimmune diseases and rehabilitation. Autoimmun Rev 11:219–225CrossRefPubMedGoogle Scholar
- 8.Sehle A, Vieten M, Sailer S et al (2014) Objective assessment of motor fatigue in multiple sclerosis: the Fatigue index Kliniken Schmieder (FKS). J Neurol 261:1752–1762CrossRefPubMedGoogle Scholar
- 9.Asano M, Finlayson ML (2014) Meta-analysis of three different types of fatigue management interventions for people with multiple sclerosis: exercise, education, and medication. Mult Scler Int. https://doi.org/10.1155/2014/798285
- 10.Heine M, van de Port I, Rietberg MB et al (2015) Exercise therapy for fatigue in multiple sclerosis. Cochrane Database Syst Rev. https://doi.org/10.1002/14651858.CD009956 PubMedGoogle Scholar
- 11.Kos D, Duportail M, D’hooghe M et al (2007) Multidisciplinary fatigue management programme in multiple sclerosis: a randomized clinical trial. Mult Scler 13:996–1003CrossRefPubMedGoogle Scholar
- 12.Finlayson M, Preissner K, Cho C et al (2011) Randomized trial of a teleconference-delivered fatigue management program for people with multiple sclerosis. Mult Scler 17:1130–1140CrossRefPubMedGoogle Scholar
- 13.Latimer-Cheung AE, Pilutti LA, Hicks AL et al (2013) Effects of exercise training on fitness, mobility, fatigue, and health-related quality of life among adults with multiple sclerosis: a systematic review to inform guideline development. Arch Phys Med Rehabil 94:1800–1828CrossRefPubMedGoogle Scholar
- 14.Thomas S, Thomas PW, Kersten P et al (2013) A pragmatic parallel arm multi-centre randomised controlled trial to assess the effectiveness and cost-effectiveness of a group-based fatigue management programme (FACETS) for people with multiple sclerosis. J Neurol Neurosurg Psychiatry 84:1092–1099CrossRefPubMedPubMedCentralGoogle Scholar
- 15.Blikman LJ, Huisstede BM, Kooijmans H et al (2013) Effectiveness of energy conservation treatment in reducing fatigue in multiple sclerosis: a systematic review and meta-analysis. Arch Phys Med Rehabil 94:1360–1376CrossRefPubMedGoogle Scholar
- 16.Thomas PW, Thomas S, Kersten P et al (2014) One year follow-up of a pragmatic multi-centre randomised controlled trial of a group-based fatigue management programme (FACETS) for people with multiple sclerosis. BMC Neurol 14:109CrossRefPubMedPubMedCentralGoogle Scholar
- 17.van Kessel K, Moss-Morris R, Willoughby E et al (2008) A randomized controlled trial of cognitive behavior therapy for multiple sclerosis fatigue. Psychosom Med 70:205–213CrossRefPubMedGoogle Scholar
- 18.Moss-Morris R, McCrone P, Yardley L et al (2012) A pilot randomised controlled trial of an Internet-based cognitive behavioural therapy self-management programme (MS Invigor8) for multiple sclerosis fatigue. Behav Res Ther 50:415–421CrossRefPubMedGoogle Scholar
- 19.Simpson R, Booth J, Lawrence M et al (2014) Mindfulness based interventions in multiple sclerosis — a systematic review. BMC Neurol 14:15CrossRefPubMedPubMedCentralGoogle Scholar
- 20.Guner S, Inanici F (2015) Yoga therapy and ambulatory multiple sclerosis assessment of gait analysis parameters, fatigue and balance. J Bodyw Mov Ther 19:72–81CrossRefPubMedGoogle Scholar
- 21.NASA MS Cooling Study Group (2003) A randomized controlled study of the acute and chronic effects of cooling therapy for MS. Neurology 60:1955–1960CrossRefGoogle Scholar
- 22.Khan F, Turner-Stokes L, Ng L et al (2007) Multidisciplinary rehabilitation for adults with multiple sclerosis. Cochrane Database Syst Rev. https://doi.org/10.1002/14651858 Google Scholar
- 23.Storr LK, Sorensen PS, Ravnborg M (2006) The efficacy of multidisciplinary rehabilitation in stable multiple sclerosis patients. Mult Scler 12:235–242CrossRefPubMedGoogle Scholar
- 24.de Carvalho ML, Motta R, Konrad G et al (2012) A randomized placebo-controlled cross-over study using a low frequency magnetic field in the treatment of fatigue in multiple sclerosis. Mult Scler 18:82–89CrossRefPubMedGoogle Scholar
- 25.Haase R, Piatkowski J, Ziemssen T (2011) Long-term effects of bio-electromagnetic-energy regulation therapy on fatigue in patients with multiple sclerosis. Altern Ther Health Med 17:22–28PubMedGoogle Scholar
- 26.Tomassini V, Pozzilli C, Onesti E et al (2004) Comparison of the effects of acetyl L‑carnitine and amantadine for the treatment of fatigue in multiple sclerosis: results of a pilot, randomised, double-blind, crossover trial. J Neurol Sci 218:103–108CrossRefPubMedGoogle Scholar
- 27.Ledinek AH, Sajko MC, Rot U (2013) Evaluating the effects of amantadin, modafinil and acetyl-L-carnitine on fatigue in multiple sclerosis — result of a pilot randomized, blind study. Clin Neurol Neurosurg 115(Suppl 1):S86–89CrossRefPubMedGoogle Scholar
- 28.Lebrun C, Alchaar H, Candito M et al (2006) Levocarnitine administration in multiple sclerosis patients with immunosuppressive therapy-induced fatigue. Mult Scler 12:321–324CrossRefPubMedGoogle Scholar
- 29.Etemadifar M, Sayahi F, Abtahi SH et al (2013) Ginseng in the treatment of fatigue in multiple sclerosis: a randomized, placebo-controlled, double-blind pilot study. Int J Neurosci 123:480–486CrossRefPubMedGoogle Scholar
- 30.Achiron A, Givon U, Magalashvili D et al (2015) Effect of alfacalcidol on multiple sclerosis-related fatigue: a randomized, double-blind placebo-controlled study. Mult Scler 21:767–775CrossRefPubMedGoogle Scholar
- 31.Shaygannejad V, Janghorbani M, Ashtari F et al (2012) Comparison of the effect of aspirin and amantadine for the treatment of fatigue in multiple sclerosis: a randomized, blinded, crossover study. Neurol Res 34:854–858CrossRefPubMedGoogle Scholar
- 32.Mucke M, Cuhls H, Peuckmann-Post V et al (2015) Pharmacological treatments for fatigue associated with palliative care. Cochrane Database Syst Rev. https://doi.org/10.1002/14651858.CD006788 PubMedGoogle Scholar
- 33.Möller F, Poettgen J, Broemel F et al (2011) HAGIL (Hamburg Vigil Study): a randomized placebo-controlled double-blind study with modafinil for treatment of fatigue in patients with multiple sclerosis. Mult Scler 17:1002–1009CrossRefPubMedGoogle Scholar
- 34.Goodman AD, Cohen JA, Cross A et al (2007) Fampridine-SR in multiple sclerosis: a randomized, double-blind, placebo-controlled, dose-ranging study. Mult Scler 13:357–368CrossRefPubMedGoogle Scholar
- 35.Goodman AD, Brown TR, Krupp LB et al (2009) Sustained-release oral fampridine in multiple sclerosis: a randomised, double-blind, controlled trial. Lancet 373:732–738CrossRefPubMedGoogle Scholar
- 36.Pucci E, Branas P, D’Amico R et al (2007) Amantadine for fatigue in multiple sclerosis. Cochrane Database Syst Rev. https://doi.org/10.1002/14651858.CD002818 PubMedGoogle Scholar
- 37.Brown JN, Howard CA, Kemp DW (2010) Modafinil for the treatment of multiple sclerosis-related fatigue. Ann Pharmacother 44:1098–1103CrossRefPubMedGoogle Scholar